The global Medication for Diabetes market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).
Medication for diabetes is a broad term that refers to any drug or treatment that helps people with diabetes manage their blood sugar levels. Blood sugar levels are affected by the amount of glucose (sugar) in the blood and the action of insulin, a hormone that helps cells use glucose for energy. People with diabetes either do not produce enough insulin, or their cells do not respond well to insulin, or both. This causes high blood sugar levels, which can lead to serious complications such as heart disease, kidney failure, nerve damage, and vision loss. Medication for diabetes aims to lower blood sugar levels to a healthy range and prevent or delay these complications.
This report studies the global Medication for Diabetes demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Medication for Diabetes, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Medication for Diabetes that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Medication for Diabetes total market, 2019-2030, (USD Million)
Global Medication for Diabetes total market by region & country, CAGR, 2019-2030, (USD Million)
U.S. VS China: Medication for Diabetes total market, key domestic companies and share, (USD Million)
Global Medication for Diabetes revenue by player and market share 2019-2024, (USD Million)
Global Medication for Diabetes total market by Type, CAGR, 2019-2030, (USD Million)
Global Medication for Diabetes total market by Application, CAGR, 2019-2030, (USD Million).
This reports profiles major players in the global Medication for Diabetes market based on the following parameters 鈥� company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Tonghua Dongbao, Gan & Lee Pharmaceuticals, Shandong Lukang Pharmaceutical, Otsuka Pharmaceutical, East China Pharmaceutical, Beilu Pharmaceutical, Furen Pharmaceutical, AstraZeneca and Novartis, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Medication for Diabetes market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.
Global Medication for Diabetes 麻豆原创, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Medication for Diabetes 麻豆原创, Segmentation by Type
Biguanides
Sulfonylureas
Thiazolidinedione
伪-Glucosidase Inhibitors
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
Insulins
Global Medication for Diabetes 麻豆原创, Segmentation by Application
Type 1 Diabetes Treatment
Type 2 Diabetes Treatment
Companies Profiled:
Tonghua Dongbao
Gan & Lee Pharmaceuticals
Shandong Lukang Pharmaceutical
Otsuka Pharmaceutical
East China Pharmaceutical
Beilu Pharmaceutical
Furen Pharmaceutical
AstraZeneca
Novartis
Novo Nordisk
Johnson & Johnson
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Merck
Sanofi
Pfizer
Astellas Pharma
Daiichi Sankyo
Biocon
Glenmark
Bayer AG
Takeda
Sun pharma
Key Questions Answered
1. How big is the global Medication for Diabetes market?
2. What is the demand of the global Medication for Diabetes market?
3. What is the year over year growth of the global Medication for Diabetes market?
4. What is the total value of the global Medication for Diabetes market?
5. Who are the major players in the global Medication for Diabetes market?
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 Supply Summary
1.1 Medication for Diabetes Introduction
1.2 World Medication for Diabetes 麻豆原创 Size & Forecast (2019 & 2023 & 2030)
1.3 World Medication for Diabetes Total 麻豆原创 by Region (by Headquarter Location)
1.3.1 World Medication for Diabetes 麻豆原创 Size by Region (2019-2030), (by Headquarter Location)
1.3.2 United States Medication for Diabetes 麻豆原创 Size (2019-2030)
1.3.3 China Medication for Diabetes 麻豆原创 Size (2019-2030)
1.3.4 Europe Medication for Diabetes 麻豆原创 Size (2019-2030)
1.3.5 Japan Medication for Diabetes 麻豆原创 Size (2019-2030)
1.3.6 South Korea Medication for Diabetes 麻豆原创 Size (2019-2030)
1.3.7 ASEAN Medication for Diabetes 麻豆原创 Size (2019-2030)
1.3.8 India Medication for Diabetes 麻豆原创 Size (2019-2030)
1.4 麻豆原创 Drivers, Restraints and Trends
1.4.1 Medication for Diabetes 麻豆原创 Drivers
1.4.2 Factors Affecting Demand
1.4.3 Medication for Diabetes Major 麻豆原创 Trends
2 Demand Summary
2.1 World Medication for Diabetes Consumption Value (2019-2030)
2.2 World Medication for Diabetes Consumption Value by Region
2.2.1 World Medication for Diabetes Consumption Value by Region (2019-2024)
2.2.2 World Medication for Diabetes Consumption Value Forecast by Region (2025-2030)
2.3 United States Medication for Diabetes Consumption Value (2019-2030)
2.4 China Medication for Diabetes Consumption Value (2019-2030)
2.5 Europe Medication for Diabetes Consumption Value (2019-2030)
2.6 Japan Medication for Diabetes Consumption Value (2019-2030)
2.7 South Korea Medication for Diabetes Consumption Value (2019-2030)
2.8 ASEAN Medication for Diabetes Consumption Value (2019-2030)
2.9 India Medication for Diabetes Consumption Value (2019-2030)
3 World Medication for Diabetes Companies Competitive Analysis
3.1 World Medication for Diabetes Revenue by Player (2019-2024)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Medication for Diabetes Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Medication for Diabetes in 2023
3.2.3 Global Concentration Ratios (CR8) for Medication for Diabetes in 2023
3.3 Medication for Diabetes Company Evaluation Quadrant
3.4 Medication for Diabetes 麻豆原创: Overall Company Footprint Analysis
3.4.1 Medication for Diabetes 麻豆原创: Region Footprint
3.4.2 Medication for Diabetes 麻豆原创: Company Product Type Footprint
3.4.3 Medication for Diabetes 麻豆原创: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of 麻豆原创 Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 United States VS China VS Rest of the World (by Headquarter Location)
4.1 United States VS China: Medication for Diabetes Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Medication for Diabetes 麻豆原创 Size Comparison (2019 & 2023 & 2030) (by Headquarter Location)
4.1.2 United States VS China: Medication for Diabetes Revenue 麻豆原创 Share Comparison (2019 & 2023 & 2030)
4.2 United States Based Companies VS China Based Companies: Medication for Diabetes Consumption Value Comparison
4.2.1 United States VS China: Medication for Diabetes Consumption Value Comparison (2019 & 2023 & 2030)
4.2.2 United States VS China: Medication for Diabetes Consumption Value 麻豆原创 Share Comparison (2019 & 2023 & 2030)
4.3 United States Based Medication for Diabetes Companies and 麻豆原创 Share, 2019-2024
4.3.1 United States Based Medication for Diabetes Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Medication for Diabetes Revenue, (2019-2024)
4.4 China Based Companies Medication for Diabetes Revenue and 麻豆原创 Share, 2019-2024
4.4.1 China Based Medication for Diabetes Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Medication for Diabetes Revenue, (2019-2024)
4.5 Rest of World Based Medication for Diabetes Companies and 麻豆原创 Share, 2019-2024
4.5.1 Rest of World Based Medication for Diabetes Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Medication for Diabetes Revenue, (2019-2024)
5 麻豆原创 Analysis by Type
5.1 World Medication for Diabetes 麻豆原创 Size Overview by Type: 2019 VS 2023 VS 2030
5.2 Segment Introduction by Type
5.2.1 Biguanides
5.2.2 Sulfonylureas
5.2.3 Thiazolidinedione
5.2.4 伪-Glucosidase Inhibitors
5.2.5 DPP-4 Inhibitors
5.2.6 GLP-1 Receptor Agonists
5.2.7 SGLT-2 Inhibitors
5.2.8 Insulins
5.3 麻豆原创 Segment by Type
5.3.1 World Medication for Diabetes 麻豆原创 Size by Type (2019-2024)
5.3.2 World Medication for Diabetes 麻豆原创 Size by Type (2025-2030)
5.3.3 World Medication for Diabetes 麻豆原创 Size 麻豆原创 Share by Type (2019-2030)
6 麻豆原创 Analysis by Application
6.1 World Medication for Diabetes 麻豆原创 Size Overview by Application: 2019 VS 2023 VS 2030
6.2 Segment Introduction by Application
6.2.1 Type 1 Diabetes Treatment
6.2.2 Type 2 Diabetes Treatment
6.3 麻豆原创 Segment by Application
6.3.1 World Medication for Diabetes 麻豆原创 Size by Application (2019-2024)
6.3.2 World Medication for Diabetes 麻豆原创 Size by Application (2025-2030)
6.3.3 World Medication for Diabetes 麻豆原创 Size by Application (2019-2030)
7 Company Profiles
7.1 Tonghua Dongbao
7.1.1 Tonghua Dongbao Details
7.1.2 Tonghua Dongbao Major Business
7.1.3 Tonghua Dongbao Medication for Diabetes Product and Services
7.1.4 Tonghua Dongbao Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.1.5 Tonghua Dongbao Recent Developments/Updates
7.1.6 Tonghua Dongbao Competitive Strengths & Weaknesses
7.2 Gan & Lee Pharmaceuticals
7.2.1 Gan & Lee Pharmaceuticals Details
7.2.2 Gan & Lee Pharmaceuticals Major Business
7.2.3 Gan & Lee Pharmaceuticals Medication for Diabetes Product and Services
7.2.4 Gan & Lee Pharmaceuticals Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.2.5 Gan & Lee Pharmaceuticals Recent Developments/Updates
7.2.6 Gan & Lee Pharmaceuticals Competitive Strengths & Weaknesses
7.3 Shandong Lukang Pharmaceutical
7.3.1 Shandong Lukang Pharmaceutical Details
7.3.2 Shandong Lukang Pharmaceutical Major Business
7.3.3 Shandong Lukang Pharmaceutical Medication for Diabetes Product and Services
7.3.4 Shandong Lukang Pharmaceutical Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.3.5 Shandong Lukang Pharmaceutical Recent Developments/Updates
7.3.6 Shandong Lukang Pharmaceutical Competitive Strengths & Weaknesses
7.4 Otsuka Pharmaceutical
7.4.1 Otsuka Pharmaceutical Details
7.4.2 Otsuka Pharmaceutical Major Business
7.4.3 Otsuka Pharmaceutical Medication for Diabetes Product and Services
7.4.4 Otsuka Pharmaceutical Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.4.5 Otsuka Pharmaceutical Recent Developments/Updates
7.4.6 Otsuka Pharmaceutical Competitive Strengths & Weaknesses
7.5 East China Pharmaceutical
7.5.1 East China Pharmaceutical Details
7.5.2 East China Pharmaceutical Major Business
7.5.3 East China Pharmaceutical Medication for Diabetes Product and Services
7.5.4 East China Pharmaceutical Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.5.5 East China Pharmaceutical Recent Developments/Updates
7.5.6 East China Pharmaceutical Competitive Strengths & Weaknesses
7.6 Beilu Pharmaceutical
7.6.1 Beilu Pharmaceutical Details
7.6.2 Beilu Pharmaceutical Major Business
7.6.3 Beilu Pharmaceutical Medication for Diabetes Product and Services
7.6.4 Beilu Pharmaceutical Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.6.5 Beilu Pharmaceutical Recent Developments/Updates
7.6.6 Beilu Pharmaceutical Competitive Strengths & Weaknesses
7.7 Furen Pharmaceutical
7.7.1 Furen Pharmaceutical Details
7.7.2 Furen Pharmaceutical Major Business
7.7.3 Furen Pharmaceutical Medication for Diabetes Product and Services
7.7.4 Furen Pharmaceutical Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.7.5 Furen Pharmaceutical Recent Developments/Updates
7.7.6 Furen Pharmaceutical Competitive Strengths & Weaknesses
7.8 AstraZeneca
7.8.1 AstraZeneca Details
7.8.2 AstraZeneca Major Business
7.8.3 AstraZeneca Medication for Diabetes Product and Services
7.8.4 AstraZeneca Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.8.5 AstraZeneca Recent Developments/Updates
7.8.6 AstraZeneca Competitive Strengths & Weaknesses
7.9 Novartis
7.9.1 Novartis Details
7.9.2 Novartis Major Business
7.9.3 Novartis Medication for Diabetes Product and Services
7.9.4 Novartis Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.9.5 Novartis Recent Developments/Updates
7.9.6 Novartis Competitive Strengths & Weaknesses
7.10 Novo Nordisk
7.10.1 Novo Nordisk Details
7.10.2 Novo Nordisk Major Business
7.10.3 Novo Nordisk Medication for Diabetes Product and Services
7.10.4 Novo Nordisk Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.10.5 Novo Nordisk Recent Developments/Updates
7.10.6 Novo Nordisk Competitive Strengths & Weaknesses
7.11 Johnson & Johnson
7.11.1 Johnson & Johnson Details
7.11.2 Johnson & Johnson Major Business
7.11.3 Johnson & Johnson Medication for Diabetes Product and Services
7.11.4 Johnson & Johnson Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.11.5 Johnson & Johnson Recent Developments/Updates
7.11.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.12 Boehringer Ingelheim
7.12.1 Boehringer Ingelheim Details
7.12.2 Boehringer Ingelheim Major Business
7.12.3 Boehringer Ingelheim Medication for Diabetes Product and Services
7.12.4 Boehringer Ingelheim Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.12.5 Boehringer Ingelheim Recent Developments/Updates
7.12.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
7.13 Bristol-Myers Squibb
7.13.1 Bristol-Myers Squibb Details
7.13.2 Bristol-Myers Squibb Major Business
7.13.3 Bristol-Myers Squibb Medication for Diabetes Product and Services
7.13.4 Bristol-Myers Squibb Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.13.5 Bristol-Myers Squibb Recent Developments/Updates
7.13.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.14 Eli Lilly
7.14.1 Eli Lilly Details
7.14.2 Eli Lilly Major Business
7.14.3 Eli Lilly Medication for Diabetes Product and Services
7.14.4 Eli Lilly Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.14.5 Eli Lilly Recent Developments/Updates
7.14.6 Eli Lilly Competitive Strengths & Weaknesses
7.15 Merck
7.15.1 Merck Details
7.15.2 Merck Major Business
7.15.3 Merck Medication for Diabetes Product and Services
7.15.4 Merck Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.15.5 Merck Recent Developments/Updates
7.15.6 Merck Competitive Strengths & Weaknesses
7.16 Sanofi
7.16.1 Sanofi Details
7.16.2 Sanofi Major Business
7.16.3 Sanofi Medication for Diabetes Product and Services
7.16.4 Sanofi Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.16.5 Sanofi Recent Developments/Updates
7.16.6 Sanofi Competitive Strengths & Weaknesses
7.17 Pfizer
7.17.1 Pfizer Details
7.17.2 Pfizer Major Business
7.17.3 Pfizer Medication for Diabetes Product and Services
7.17.4 Pfizer Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.17.5 Pfizer Recent Developments/Updates
7.17.6 Pfizer Competitive Strengths & Weaknesses
7.18 Astellas Pharma
7.18.1 Astellas Pharma Details
7.18.2 Astellas Pharma Major Business
7.18.3 Astellas Pharma Medication for Diabetes Product and Services
7.18.4 Astellas Pharma Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.18.5 Astellas Pharma Recent Developments/Updates
7.18.6 Astellas Pharma Competitive Strengths & Weaknesses
7.19 Daiichi Sankyo
7.19.1 Daiichi Sankyo Details
7.19.2 Daiichi Sankyo Major Business
7.19.3 Daiichi Sankyo Medication for Diabetes Product and Services
7.19.4 Daiichi Sankyo Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.19.5 Daiichi Sankyo Recent Developments/Updates
7.19.6 Daiichi Sankyo Competitive Strengths & Weaknesses
7.20 Biocon
7.20.1 Biocon Details
7.20.2 Biocon Major Business
7.20.3 Biocon Medication for Diabetes Product and Services
7.20.4 Biocon Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.20.5 Biocon Recent Developments/Updates
7.20.6 Biocon Competitive Strengths & Weaknesses
7.21 Glenmark
7.21.1 Glenmark Details
7.21.2 Glenmark Major Business
7.21.3 Glenmark Medication for Diabetes Product and Services
7.21.4 Glenmark Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.21.5 Glenmark Recent Developments/Updates
7.21.6 Glenmark Competitive Strengths & Weaknesses
7.22 Bayer AG
7.22.1 Bayer AG Details
7.22.2 Bayer AG Major Business
7.22.3 Bayer AG Medication for Diabetes Product and Services
7.22.4 Bayer AG Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.22.5 Bayer AG Recent Developments/Updates
7.22.6 Bayer AG Competitive Strengths & Weaknesses
7.23 Takeda
7.23.1 Takeda Details
7.23.2 Takeda Major Business
7.23.3 Takeda Medication for Diabetes Product and Services
7.23.4 Takeda Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.23.5 Takeda Recent Developments/Updates
7.23.6 Takeda Competitive Strengths & Weaknesses
7.24 Sun pharma
7.24.1 Sun pharma Details
7.24.2 Sun pharma Major Business
7.24.3 Sun pharma Medication for Diabetes Product and Services
7.24.4 Sun pharma Medication for Diabetes Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
7.24.5 Sun pharma Recent Developments/Updates
7.24.6 Sun pharma Competitive Strengths & Weaknesses
8 Industry Chain Analysis
8.1 Medication for Diabetes Industry Chain
8.2 Medication for Diabetes Upstream Analysis
8.3 Medication for Diabetes Midstream Analysis
8.4 Medication for Diabetes Downstream Analysis
9 Research Findings and Conclusion
10 Appendix
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
Tonghua Dongbao
Gan & Lee Pharmaceuticals
Shandong Lukang Pharmaceutical
Otsuka Pharmaceutical
East China Pharmaceutical
Beilu Pharmaceutical
Furen Pharmaceutical
AstraZeneca
Novartis
Novo Nordisk
Johnson & Johnson
Boehringer Ingelheim
Bristol-Myers Squibb
Eli Lilly
Merck
Sanofi
Pfizer
Astellas Pharma
Daiichi Sankyo
Biocon
Glenmark
Bayer AG
Takeda
Sun pharma
听
听
*If Applicable.
